Label composition: BPC-157 · TB-500
BPC-157 + TB-500 Peptide Stack
$119.00
Wolverine brings BPC-157 and TB-500 together in one distinctive two-compound stack. The formulation pairs two familiar names from recovery-focused research in one clearly identified product.
18 in stock
Wolverine brings BPC-157 and TB-500 together in one distinctive two-compound stack. The formulation pairs two familiar names from recovery-focused research in one clearly identified product.
Understand the formulation
The selected references examine BPC-157 and thymosin beta-4 research separately. The available evidence is largely preclinical, and these component studies do not establish an outcome for the Wolverine formulation.
Systematic review · predominantly preclinical
A systematic review found that nearly all included BPC-157 studies were preclinical and reported no clinical safety data.
PubMed (PMID 40756949)
Review authoritative source : PubMed (PMID 40756949)Review · preclinical and limited clinical context
A peer-reviewed review discusses dermal-healing research across preclinical models and limited phase 2 studies. It concerns thymosin beta-4 research, not proof of this finished stack.
PubMed (PMID 27450738)
Review authoritative source : PubMed (PMID 27450738)Research references describe the cited compounds or biological context; they do not establish a guaranteed outcome for this product or formulation.
